CAR therapies Jan 11, 2023 Bio4t2 Begins Dosing Solid Tumor Patients in First-In-Human CAR T-Cell Therapy Trial Jan 9, 2023 2seventy, Bristol Myers Squibb Improving Manufacturing Capacity for Abecma Jan 6, 2023 Arsenal Biosciences Begins Phase I Trial of Cell Therapy in Ovarian Cancer Jan 3, 2023 China's NMPA Accepts New Drug Application for Legend Biotech, Janssen's Carvykti Dec 22, 2022 FDA Clears Iaso Biotherapeutics for US Trials of BCMA-Targeted CAR-T Therapy in Multiple Myeloma Dec 22, 2022 OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia Dec 21, 2022 Cedars-Sinai Sets Up New Precision Oncology-Focused Lymphoma Program Dec 20, 2022 Gilead Sciences to Acquire Cell Therapy Biotech Tmunity Therapeutics Dec 20, 2022 Invectys, CTMC Begin First-in-Human Trial of HLA-G-Targeting CAR T-Cell Therapy in Solid Tumors Dec 16, 2022 In Brief This Week: Casi Pharmaceuticals, Cofactor Genomics, Point32Health Dec 15, 2022 Immix Biopharma Forms New Subsidiary, In-Licenses Multiple Myeloma CAR T-Cell Therapy Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Dec 12, 2022 ASH Data Suggests CAR T is Best Option for Lymphoma Patients Expressing Both MYC, BCL-2 Premium Dec 11, 2022 Bristol Myers Squibb, 2seventybio's Abecma Shows Benefit in High-Risk Multiple Myeloma Patients Premium Dec 9, 2022 Gilead Sciences, Arcellx Ink Deal to Co-Develop, Commercialize Multiple Myeloma CAR T-Cell Therapy Dec 8, 2022 Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences Nov 23, 2022 Coeptis Therapeutics Partners With IQVIA to Advance CAR T-Cell Therapy Into Clinic Nov 22, 2022 Legend Biotech to Launch CAR T-Cell Therapy Trial for Small Cell Lung Cancer, Neuroendocrine Tumors Nov 10, 2022 CAR T Cells Targeting CD19, CD22 Yield Encouraging Responses in Children With Leukemia Premium Nov 8, 2022 Ono Pharmaceutical Exercises Option to Jointly Develop CAR T-Cell Therapy With Fate Therapeutics Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer